PMC10157226_01
Fluorodeoxyglucose-positron emission tomography/computed tomography findings at the initial visit to our department for the patient with human epidermal growth factor receptor 2-positive breast cancer. (A) High FDG accumulation in the level I-II region of the right axilla (red arrow) (B) High FDG accumulation in the upper outer quadrant of the right breast (red arrow) (C) Numerous foci of high FDG accumulation in the liver (red arrows). (D) High FDG accumulation in the left iliac bone (red arrow). (E) Enlarged lymph node in the level I-II region of the right axilla (yellow arrow). (F) Mass in the upper outer right breast (yellow arrow). (G) Multiple low density areas in the liver (yellow arrows). (H) Low density area in pelvic region (yellow arrow).
fonc-13-1158797-g001.jpg
PMC10157226_01_fonc-13-1158797-g001.jpg
f1
FDG-PET/CT revealed high FDG accumulation in the upper outer quadrant of the right breast (standardized uptake value (SUV) max, 7.519), enlarged lymph nodes, and high FDG accumulation in the level I-II region of the right axilla and internal mammary lymph node region (SUV max, 3.525), numerous low-density areas with high FDG accumulation in the liver (SUV max, 7.816), and high FDG accumulation in the left iliac bone (SUV max, 7.356) (Figure 1). However, FDG-PET performed in March 201X+1 did not detect abnormal uptake of FDG in the hepatic lesions (Figure 2; Supplementary Figure 1).
Course of treatment and imaging changes in multiple liver metastases for the patient with human epidermal growth factor receptor 2-positive breast cancer.
fonc-13-1158797-g002.jpg
PMC10157226_01_fonc-13-1158797-g002.jpg
f2
CEA and CA15-3 levels were 90.2 ng/mL and 33.0 IU/mL, respectively. CT performed in the same period showed cystic changes in the metastatic lesions in the liver, and the treatment response was stable disease according to RECIST (Figure 2). However, FDG-PET performed in March 201X+1 did not detect abnormal uptake of FDG in the hepatic lesions (Figure 2; Supplementary Figure 1). CT performed in June 201X+1 showed shrinkage of the liver metastases, and the disease remained stable for more than three years (Figure 2).